Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: a systematic review and economic evaluation

Abstract

How to obtain copies of this and other HTA programme reports An electronic version of this title, in Adobe Acrobat format, is available for downloading free of charge for personal use from the HTA website (www.hta.ac.uk). A fully searchable DVD is also available (see below).Printed copies of HTA journal series issues cost £20 each (post and packing free in the UK) to both public and private sector purchasers from our despatch agents.Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per issue and for the rest of the world £3 per issue. How to order:-fax (with credit card details) -post (with credit card details or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you to either print out your order or download a blank order form. Contact details are as follows:Synergie UK (HTA Department) Digital House, The Loddon Centre Wade Road Basingstoke Hants RG24 8QW Email: orders@hta.ac.uk Tel: 0845 812 4000 -ask for 'HTA Payment Services' (out-of-hours answer-phone service) Fax: 0845 812 4001 -put 'HTA Order' on the fax header Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to University of Southampton and drawn on a bank with a UK address.Paying by credit card You can order using your credit card by phone, fax or post. SubscriptionsNHS libraries can subscribe free of charge. Public libraries can subscribe at a reduced cost of £100 for each volume (normally comprising 40-50 titles). The commercial subscription rate is £400 per volume (addresses within the UK) and £600 per volume (addresses outside the UK). Please see our website for details. Subscriptions can be purchased only for the current or forthcoming volume.How do I get a copy of HTA on DVD?Please use the form on the HTA website (www.hta.ac.uk/htacd/index.shtml). HTA on DVD is currently free of charge worldwide.The website also provides information about the HTA programme and lists the membership of the various committees. ii ii HTA NIHR Health Technology Assessment programmeThe Health Technology Assessment (HTA) programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care. The research findings from the HTA programme directly influence decision-making bodies such as the National Institute for Health and Clinical Excellence (NICE) and the National Screening Committee (NSC). HTA findings also help to improve the quality of clinical practice in the NHS indirectly in that they form a key component of the 'National Knowledge Service' . The HTA programme is needs led in that it fills gaps in the evidence needed by the NHS. There are three routes to the start of pro...

Effect of TNF-α inhibitors on transcriptional levels of pro-inflammatory interleukin-33 and Toll-like receptors-2 and -9 in psoriatic plaques

“…In the present study, the efficacy of the TNF-α inhibitors etanercept and infliximab in plaque psoriasis therapy has been clearly demonstrated, in agreement with previous studies (2)(3)(4)(5)(6). Furthermore, concerning the small number of infliximab-treated cases or female patients, this study revealed notable observations regarding correlations among pro-inflammatory genes, anti-TNF-α treatment type and gender.…”

“…Treatment of severe psoriatic plaques may involve biological agents that block the action of tumor necrosis factor (TNF)-α, such as etanercept and infliximab (2)(3)(4)(5)(6). Etanercept is a recombinant human TNF-receptor fusion protein that binds free TNF-α (7,8).…”

Certolizumab pegol and secukinumab for treating active psoriatic arthritis following inadequate response to disease-modifying antirheumatic drugs: a systematic review and economic evaluation

“…Review of the natural history of psoriatic arthritis: registry and cohort study data A total of four publications 33,[98][99][100] analysing patterns of natural disease progression in registries or long-term cohort data were found and are shown in Table 36. These were reviewed in order to gain an understanding of the manner in which disease progresses in patients who do not receive anti-TNF therapy, despite being eligible for treatment.…”

“…Owing to the now ubiquitous nature of anti-TNFs and only recent recognition of PsA as a separate and distinct form of arthritis, information on the long-term uncontrolled progression of the disease is scarce. Two of the studies 33,100 found in the literature search were different analyses of the same data set derived from the Norfolk Arthritis Register (NOAR): one was a 2-year prospective cohort study 99 and the other a retrospective analysis of a Canadian single-site patient registry. 98 The studies explore changes in functional disability in terms of HAQ-DI score and bone erosion as measures of disease activity and progression over time.…”

“…The patients in this analysis may or may not have been treated with DMARDs over this period. The analysis in Rodgers et al 33 includes only those patients who had previously received two or more DMARDs at each time point, finding an annual HAQ-DI score change of -0.060 units per year over the first 2 years (n = 24), and an annual increase of 0.077 units over years 3 to 5 (n = 52). This represents a faster progression of disease than that found in the Morgan et al 100 study, but is inconsistent and derived from a small cohort of varying size.…”